Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Based on early human studies and animal research, GLP-1 agonists may affect: Reward-related eating behaviours by potentially modulating dopamine signalling in brain reward circuits Food cravings and hedonic eating (eating for pleasure rather than hunger) Impulsivity around food , possibly reducing the compulsive aspects of eating Satiety signalling , enhancing the feeling of fullness after meals Some patients using GLP-1 medications for diabetes or weight management report not just reduced appetite but also diminished preoccupation with food, fewer intrusive thoughts about eating, and reduced cravings for specific foods, particularly those high in fat and sugar
Medications prescribed include (Mochi Health) GLP-1/GIP & GLP-1 injectables: Zepbound / Mounjaro (tirzepatide)
Ibrance (palbociclib) Disease area(s): Oncology Manufacturer(s): Pfizer 2024 Sales (USD): $4.37 billion Why it sold so well: Pfizers Ibrance generated $4.37 billion in global revenue in 2024, maintaining its position as a leading therapy for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer
Liposuction permanently removes fat cells from treated areas, but untreated areas can still expand if your weight increases
Inform your clinician if you are using: Copper supplements or high-dose antioxidants Hormone therapies Other injectable peptides or regenerative treatments Common questions (FAQ) What does COA mean
